LOS ANGELES--(EON: Enhanced Online News)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Novocure Limited (“Novocure” or the “Company”) (Nasdaq: NVCR) concerning possible violations of federal securities laws.
“[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at firstname.lastname@example.org.
Novocure creates and markets treatment for solid tumor cancers therapy called the tumor treating fields (“TTFields”). Novocure advertises its proprietary therapy, TTFields delivery system, through the Optune name as a monotherapy treatment for adult patients with glioblastoma brain cancer.
Novocure revealed that its new Optune prescriptions dropped to 657 in the second quarter from 755 in the first. Asaf Danziger, Chief Executive Officer of Novocure, stated “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
When this information was revealed to the public, Novocure’s stock fell over 29%, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.